Cell therapies are in the process of revolutionizing the medical field. Last February, a pioneer of cell therapy, Carl June, reported that the second patient to ever receive a chimeric antigen ...
SOUTH SAN FRANCISCO, Calif. & LONDON--(BUSINESS WIRE)--Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...
Collaboration with Stanford Medicine establishes a platform manufacturing process and analytics designed to support gene-edited hematopoietic stem cell therapies for HIV and more than 19 rare diseases ...
Lyell Immunopharma will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program. As part of the collaboration, the ...
As demand for CAR T therapies strain traditional manufacturing, Autolus Therapeutics has tapped Cellares to evaluate whether that company’s automated Cell Shuttle platform can support expanded ...
Cell and Gene Therapy Catapult’s Stevenage Manufacturing Innovation Centre Photo credit: Cell and Gene Therapy Catapult The first facility, housed within the Cell and Gene Therapy Catapult’s (CGT ...
Sony and Cellares announced a joint development collaboration Sept. 12. The two companies say the partnership aims to integrate Sony’s cell-sorting and analytical technologies into the Cell Shuttle, ...
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced a collaboration with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford ...
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results